📊 TVTX Key Takeaways
Is Travere Therapeutics, Inc. (TVTX) a Good Investment?
Travere demonstrates exceptional revenue growth (+110.5% YoY) with rapidly improving losses (net income +92.1% YoY), indicating successful commercialization and a trajectory toward profitability. However, significant operating cash burn (-$40.4M) against limited cash reserves creates material execution risk that requires sustained margin expansion and revenue momentum.
Why Buy Travere Therapeutics, Inc. Stock? TVTX Key Strengths
- Exceptional revenue growth of 110.5% YoY demonstrating strong product market fit and commercialization success
- Rapidly improving profitability with net income losses improving 92.1% YoY, suggesting movement toward breakeven
- Strong liquidity position with 3.13x current ratio, $78.4M cash, and conservative 0.23x debt-to-equity leverage
TVTX Stock Risks: Travere Therapeutics, Inc. Investment Risks
- Operating cash burn of $40.4M provides limited runway relative to $78.4M cash reserves at current burn rates
- Company remains significantly unprofitable with -29.2% net margin despite strong revenue growth, indicating cost structure requires further optimization
- Pharmaceutical regulatory and clinical execution risks could disrupt commercialization trajectory and cash burn trajectory
Key Metrics to Watch
- Operating cash flow and burn rate trajectory - must improve to extend runway and validate unit economics
- Operating margin expansion path - critical indicator of whether revenue growth translates to sustainable profitability
- Revenue growth sustainability - must maintain momentum to support cash runway and competitive positioning
Travere Therapeutics, Inc. (TVTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.13x current ratio provides a solid financial cushion.
TVTX Profit Margin, ROE & Profitability Analysis
TVTX vs Healthcare Sector: How Travere Therapeutics, Inc. Compares
How Travere Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Travere Therapeutics, Inc. Stock Overvalued? TVTX Valuation Analysis 2026
Based on fundamental analysis, Travere Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Travere Therapeutics, Inc. Balance Sheet: TVTX Debt, Cash & Liquidity
TVTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Travere Therapeutics, Inc.'s revenue has grown significantly by 116% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.50 indicates the company is currently unprofitable.
TVTX Revenue Growth, EPS Growth & YoY Performance
TVTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $81.7M | -$37.1M | $-0.40 |
| Q3 2025 | $62.9M | $25.7M | $0.28 |
| Q2 2025 | $54.1M | -$12.8M | $-0.14 |
| Q1 2025 | $41.4M | -$41.2M | $-0.47 |
| Q3 2024 | $37.1M | -$21.2M | $-0.29 |
| Q2 2024 | $32.2M | -$70.4M | $-0.91 |
| Q1 2024 | $30.9M | -$86.3M | $-1.27 |
| Q3 2023 | $28.1M | -$21.2M | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Travere Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TVTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Travere Therapeutics, Inc. (CIK: 0001438533)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TVTX
What is the AI rating for TVTX?
Travere Therapeutics, Inc. (TVTX) has an AI rating of HOLD with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TVTX's key strengths?
Claude: Exceptional revenue growth of 110.5% YoY demonstrating strong product market fit and commercialization success. Rapidly improving profitability with net income losses improving 92.1% YoY, suggesting movement toward breakeven.
What are the risks of investing in TVTX?
Claude: Operating cash burn of $40.4M provides limited runway relative to $78.4M cash reserves at current burn rates. Company remains significantly unprofitable with -29.2% net margin despite strong revenue growth, indicating cost structure requires further optimization.
What is TVTX's revenue and growth?
Travere Therapeutics, Inc. reported revenue of $127.2M.
Does TVTX pay dividends?
Travere Therapeutics, Inc. does not currently pay dividends.
Where can I find TVTX SEC filings?
Official SEC filings for Travere Therapeutics, Inc. (CIK: 0001438533) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TVTX's EPS?
Travere Therapeutics, Inc. has a diluted EPS of $-0.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TVTX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Travere Therapeutics, Inc. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TVTX stock overvalued or undervalued?
Valuation metrics for TVTX: ROE of -37.6% (sector avg: 15%), net margin of -29.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TVTX stock in 2026?
Our dual AI analysis gives Travere Therapeutics, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TVTX's free cash flow?
Travere Therapeutics, Inc.'s operating cash flow is $-40.4M, with capital expenditures of $375.0K. FCF margin is -32.0%.
How does TVTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -29.2% (avg: 12%), ROE -37.6% (avg: 15%), current ratio 3.13 (avg: 2).